After Abiomed presented data demonstrating that unloading the left ventricle with Impella CP for 30 minutes prior to reperfusion in STEMI patients without cardiogenic shock is safe and feasible, Stephens analyst Chris Cooley called the study results "very promising" and sees the potential for a pivotal trial to increase the company's addressable market by about 250,000 patients annually. He views the pullback in Abiomed shares reflecting broader market trends impacting higher-growth and multiple stocks, rather than disappointment with the data, Cooley tells investors. He reiterates an Overweight rating and $415 price target on Abiomed shares.